24–48 hours
Intravenous recipients commonly report energy and clarity changes; subcutaneous effects are reported as slower.
Protocol / Research Dosing Guide
NAD+ Dosage Guide: Routes, Reconstitution and Evidence Boundaries
An evidence-organized NAD+ reference separating the strong oral-precursor trial base from the thinner evidence behind injectable NAD+.
Last reviewed September 16, 202620 minute readResearch information only
Level 5 — Randomized trials for oral precursorsLimited evidence for injectionInjectable NAD+ is not FDA approved
NAD+ Quick Start
NAD+ is a coenzyme present in every cell, used to move electrons during energy production, to fuel PARP-driven DNA repair and to power the sirtuin enzyme family. It is grouped with peptide protocols only because it shares the injectable research-use format. The evidence split matters: oral precursors have a solid randomized base for raising blood NAD+, while direct injectable NAD+ has limited published human data.
Why researchers care
Cellular energy, DNA repair, sirtuin activity and longevity research
Class
Nicotinamide adenine dinucleotide, a coenzyme — not a peptide
Route reported
Subcutaneous, intramuscular, intravenous, oral precursors, intranasal or sublingual
Cycle length
4, 8 or 12 week planning frameworks; no established requirement to cycle
Regulatory status
Injectable NAD+ is not FDA approved as a therapeutic; oral precursors are sold as supplements
Loading supplier information
NAD+ Dosing Protocol and Schedule
The supplied source reports subcutaneous research planning of 50–100 mg per injection two to three times weekly, with a titration reference of 50 mg, then 75 mg, then 100 mg. Intravenous ranges are 250–500 mg weekly to biweekly in maintenance and 500–1,000 mg in higher-dose clinic protocols, infused slowly over two to four hours.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Subcutaneous assessment | 50 mg, once or three times weekly | Clinic and community planning |
| Subcutaneous titration | 75 mg, one to three times weekly | Clinic and community planning |
| Subcutaneous maintenance | 100 mg, two to three times weekly | Clinic and community planning |
| Intensive loading | 100–200 mg daily for 7–10 days | Supervised settings only |
| Intramuscular | 50–100 mg, one to three times weekly | Clinic and community planning |
| Intravenous maintenance | 250–500 mg, weekly to biweekly | Published pilot work and clinic practice |
| Oral NR | 300–1,000 mg daily | Human randomized trials |
| Oral NMN | 300–900 mg daily | Human randomized trials |
Some planning frameworks cap weekly subcutaneous totals near 300 mg without further evaluation. Injection rate matters as much as amount: slow injection over 5–10 seconds and site rotation are the reported ways to reduce stinging and nodules.
NAD+ Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled NAD+ vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
U-100 insulin syringes
Research planning item
A larger mixing syringe for the water draw
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
NAD+ Reconstitution Calculator
Vial-format concentration math
Concentration
100 mg/mL
Draw volume
1 mL
U-100 units
100
Mathematical draws
5
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take NAD+: Morning or Night?
Morning or evening?
Morning is commonly preferred; later injection is reported to disturb sleep.
Daily or spaced?
Subcutaneous planning is two to three times weekly; oral precursors are daily; intravenous is weekly to monthly.
With food?
Not applicable to injection. Oral precursors are taken daily per the trial designs.
Missed amount?
No validated replacement procedure exists for the injectable route.
NAD+ Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous | 50–100 mg per session, two to three times weekly | Direct subcutaneous evidence is limited |
| Intramuscular | 50–100 mg, one to three times weekly | No published head-to-head route comparison |
| Intravenous | 250–500 mg maintenance; 500–1,000 mg in higher-dose clinic protocols over 2–4 hours | Clinic-administered; pilot pharmacokinetic data |
| Oral precursors (NR, NMN) | 300–1,000 mg daily | The strongest randomized human base |
| Intranasal or sublingual | 50–200 mg per dose | Limited published evidence; pharmacy-prepared |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
NAD+ Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Injectable NAD+ half-life | Not fully characterized in published human pharmacokinetics | Do not infer frequency |
| Intravenous exposure | A 750 mg three-hour infusion was reported to raise blood NAD+ by about 398% over baseline in pilot work | Single pilot report |
| Oral precursor kinetics | Raise blood NAD+ more gradually than injection | Established in randomized trials |
| Frequency logic | Weekly patterns are planning conventions rather than pharmacokinetic conclusions | Not established |
NAD+ Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 50 mg | Once or three times weekly | Clinic/community planning | No |
| Subcutaneous | 100 mg | Two to three times weekly | Clinic/community planning | No |
| Intravenous | 250–500 mg | Weekly to biweekly | Clinic practice and pilot research | Clinic administered |
| Oral NR | 300–1,000 mg | Daily | Human randomized trials | Trial design |
| Oral NMN | 300–900 mg | Daily | Human randomized trials | Trial design |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
NAD+ Reconstitution Guide
Concentration: 100 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 100 mg | 1 mL | 100 units |
| 200 mg | 2 mL | 200 units |
| 300 mg | 3 mL | 300 units |
- 1.Confirm the labeled quantity on the vial.
- 2.Choose and record the bacteriostatic water volume; 500 mg into 5 mL gives 100 mg/mL.
- 3.Clean the stopper with an alcohol swab.
- 4.Draw the planned water volume with a sterile syringe.
- 5.Inject it down the inside wall of the vial rather than onto the powder, to reduce foaming.
- 6.Roll or swirl slowly until dissolved; do not shake hard.
- 7.Inspect for clarity and discard anything discolored or cloudy.
- 8.Label with the concentration and date, then refrigerate at 2–8 °C.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How NAD+ Works
Energy production
Mitochondria use NAD+ to shuttle electrons through the electron transport chain; when it falls, ATP production is less efficient.
NAD+ Human Trials and FDA Status
Current status · verified September 16, 2026
Injectable NAD+ is not FDA approved as a therapeutic; oral precursors are sold as supplements
- Multiple randomized trials of oral nicotinamide riboside (Martens 2018, Conze 2019, Dollerup 2018, Brakedal 2022) raised blood NAD+ with favorable tolerability at up to 1,000 mg daily.
- Yoshino 2021 reported improved muscle insulin sensitivity with 250 mg/day oral NMN in postmenopausal women.
- A 2022 dose-response randomized trial of NMN at 300, 600 and 900 mg/day raised NAD+ dose-dependently over 60 days, with the largest effect at 600 mg.
- Direct injectable evidence is limited to historical intravenous case reports and pilot pharmacokinetic comparisons.
- A 2024 systematic review in the American Journal of Physiology found insufficient high-quality evidence for routine subcutaneous NAD+ practice.
Who Should Avoid NAD+?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy and breastfeeding
Insufficient safety data
Active malignancy
NAD+ supports cellular proliferation; oncologist consultation is described as essential
Severe liver or kidney impairment
High-dose protocols may add metabolic burden
Known hypersensitivity to formulation components or bacteriostatic water preservatives
Allergy risk
Concurrent high-dose niacin
Overlapping pathway load warrants clinician review
People on glucose-lowering medicines
Insulin sensitivity may shift; closer glucose monitoring is prudent
NAD+ Side Effects, Risks and Safety
Injection-site stinging, burning or nodulesCommonly reported with subcutaneous use
Important limitation: Managed with slow injection and site rotation.
Nausea, headache or flushingReported during early titration
Important limitation: Often amount- and rate-dependent.
Temporary fatigueReported
Important limitation: Most common in the first few sessions.
Sleep disruptionReported
Important limitation: Associated with later-in-the-day administration.
Flushing, chest tightness or rapid heart rate with intravenous useReported
Important limitation: Associated with faster infusion rates.
Long-term high-dose injectable safetyUnknown
Important limitation: Limited published human data.
NAD+ Timeline and Monitoring
Weeks 1–4
Energy and sleep are the most commonly reported subjective endpoints during titration.
Weeks 4–12
Recovery, exercise capacity and skin reports emerge anecdotally; randomized outcome data for direct injection is lacking.
Monitoring
Sleep, subjective energy, injection-site appearance, liver markers in extended high-dose protocols, and glucose markers if taking glucose-lowering medicines.
NAD+ Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Raising blood NAD+ | Human randomized trials | Oral NR and NMN raise NAD+ reliably | Established for precursors, not injection |
| Insulin sensitivity | Human randomized trial | 250 mg/day NMN in postmenopausal women | Single population |
| Energy and recovery from injection | Anecdotal | Clinic and community reports | No randomized confirmation |
| Longevity outcomes | Not established | Animal biomarker reversal does not equal a human outcome | Unsupported claim |
NAD+ Storage and Handling
Lyophilized powder
Room temperature, dry and dark is acceptable short-term per manufacturer labeling; refrigeration is the long-term option.
Prepared vial
2–8 °C with a typical 14–30 day window depending on compounder guidance.
Pre-mixed pharmacy liquid
Follow the pharmacy beyond-use date.
Appearance
Discard if discolored or cloudy.
NAD+ Troubleshooting
Stinging during subcutaneous injection
Inject more slowly, over 5–10 seconds or longer, and rotate sites across abdominal quadrants, upper arm and outer thigh.
Nodules or lipohypertrophy
Reported as a site-rotation problem rather than an amount problem.
Sleep disruption
Associated with later-day administration; morning timing is the reported preference.
Foaming during mixing
Aim the water stream down the vial wall rather than onto the powder.
Side effects persist after slowing injection
Reported practice is to pause, reassess and consult a clinician before resuming.
Oral and injectable figures confused
They are different routes with different evidence; milligram figures are not interchangeable.
NAD+ Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Injectable NAD+ | Direct coenzyme delivery | Limited human evidence | Not FDA approved |
| Oral NR | NAD+ precursor | Multiple randomized trials raising blood NAD+ | Sold as a supplement |
| Oral NMN | NAD+ precursor | Dose-response randomized data up to 900 mg/day | Regulatory status varies |
| Intravenous NAD+ | Highest peak levels | Pilot pharmacokinetics; clinic administered | Not FDA approved |
NAD+ Frequently Asked Questions
Is NAD+ a peptide?
No. It is a coenzyme. It is grouped with peptide protocols because it shares the injectable research-use format.
Is injectable NAD+ FDA approved?
No.
What subcutaneous range is reported?
50–100 mg per injection, two to three times weekly, often after a 50 mg assessment phase.
What is reported for intravenous use?
250–500 mg weekly to biweekly, or 500–1,000 mg in higher-dose clinic protocols, infused over two to four hours.
Why does injection sting?
Subcutaneous NAD+ commonly produces brief rate-dependent stinging; slower injection is the reported remedy.
Do oral capsules work?
Oral NAD+ does not survive digestion intact. Published trials use the precursors NR and NMN.
Does it need to be cycled?
No requirement is established. Frequency adjustment with periodic review is one reported approach.
What should be monitored?
Sleep, energy, injection sites, liver markers in extended high-dose protocols and glucose markers if on glucose-lowering medicines.
Who should avoid it?
People with active malignancy, severe liver or kidney impairment, or who are pregnant or breastfeeding, without clinician oversight.
What does the calculator do?
Concentration and volume arithmetic only.
Sources and Research
Coverage source
1. NAD+ protocol coverage source
Route-by-route planning ranges, titration reference and reconstitution math; not primary evidence.
Open direct sourceHuman research
2. Martens et al., Chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults
Randomized controlled trial of an oral precursor.
Open direct sourceHuman research
3. Yoshino et al., NMN increases muscle insulin sensitivity in prediabetic women
Randomized trial at 250 mg/day.
Open direct sourceReview
4. Covarrubias et al., NAD+ metabolism and its roles in cellular processes during ageing
Nature Reviews Molecular Cell Biology review of NAD+ decline and sirtuin/PARP/CD38 biology.
Open direct sourceMissing information flagged for review
- Randomized trials of subcutaneous NAD+ for wellness or longevity endpoints: Not established
- Human pharmacokinetics and half-life for injection: Not established
- Head-to-head route comparison data: Not established
- Validated cycle structure: Not established
- Long-term high-dose injectable safety: Not established
- Drug interaction data: Not established